Thursday, January 21, 2016 1:31:37 PM
"I typically stay away from small pharma stocks for a simple reason. Almost all lose money and are just searching for that one single product that will make them profitable."
That's epidiolex! Only 4 analyst, (US analysts) cover the stock.. They haven't come close to projecting the amount of money will lose.. Q3 of 2014 the project over a $1 loss and the reported a beat by $.50.. That large deviation leads me to believe that these analysts are throwing out the worst case projecting.. FX exchange playing a huge factor for the inaccuracies..
Regard to buyouts, I truly believe that if a company wanted to gamble with $2 billion to increase their pipeline and have a monopoly in the CBD space (until patent protect runs out) this is the time for them to step up to the plate. Given the very limit medical uses for cannabis in this country, and increasing law towards the substance, this could one day be a blockbuster drug
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM